1 Pleyer, C., H. Bittner, G. R. Locke, R. S. Choung, A. R. Zinsmeister, C. D. Schleck, L. M. Herrick, and N. J. Talley. 2014. “Overdiagnosis of Gastro-Esophageal Reflux Disease and Underdiagnosis of Functional Dyspepsia in a USA Community.” Neurogastroenterology and Motility 26 (8): 1163–71. doi:10.1111/nmo.12377.

2 Talley, NJ, MM Walker, and G Holtmann. 2016. “Functional Dyspepsia.” Curr Opin Gastroenterol 32 (4): 467–73. doi:10.1016/0300-2977(95)00099-9.

3 Stanghellini, Vincenzo, Francis K L Chan, William L. Hasler, Juan R. Malagelada, Hidekazu Suzuki, Jan Tack, and Nicholas J. Talley. 2016. “Gastroduodenal Disorders.” Gastroenterology 150 (6). Elsevier, Inc: 1380–92. doi:10.1053/j.gastro.2016.02.011.

4 Talley, Nicholas J. 2017. “Functional Dyspepsia: Advances in Diagnosis and Therapy.” Gut and Liver 11 (3): 349–57.

5 Groschwitz, Katherine R, and Simon P Hogan. 2009. “Intestinal Barrier Function: Molecular Regulation and Disease Pathogenesis.” The Journal of Allergy and Clinical Immunology 124 (1): 3-20-2. doi:10.1016/j.jaci.2009.05.038.

6 Juergens, UR, M Stober, and H Vetter. 1998. “The Anti-Inflammatory Activity of L-Menthol Compared to Mint Oil in Human Monocytes in Vitro: A Novel Perspective for Its Therapeutic Use in Inflammatory Diseases.” European Journal of Medical Research 3 (12): 539–45.

7 Goerg, K. J., and Th Spilker. 2003. “Effect of Peppermint Oil and Caraway Oil on Gastrointestinal Motility in Healthy Volunteers: A Pharmacodynamic Study Using Simultaneous Determination of Gastric and Gall-Bladder Emptying and Orocaecal Transit Time.”Alimentary Pharmacology and Therapeutics. doi:10.1046/j.1365-2036.2003.01421.x.

8 Rozza, Ariane Leite, Felipe Meira De Faria, Alba Regina Souza Brito, Clá Udia, and Helena Pellizzon. 2014. “The Gastroprotective Effect of Menthol: Involvement of Anti-Apoptotic, Antioxidant and Anti-Inflammatory Activities.” PLoS ONE 9 (1): 1–6. doi:10.1371/journal.pone.0086686.

9 Baananou, Sameh, Edita Bagdonaite, Bruno Marongiu, Alessandra Piras, Silvia Porcedda, Danilo Falconieri, and Naceur Boughattas. 2013. “Extraction of the Volatile Oil from Carum Carvi of Tunisia and Lithuania by Supercritical Carbon Dioxide: Chemical Composition and Antiulcerogenic Activity.” Natural Product Research 27 (22): 2132–36. doi:10.1080/14786419.2013.771350.

10 Adam, Birgit, Tobias Liebregts, Jan Best, Lars Bechmann, Carolin Lackner, Jens Neumann, Stephan Koehler, and Gerald Holtmann. 2006. “A Combination of Peppermint Oil and Caraway Oil Attenuates the Post-Inflammatory Visceral Hyperalgesia in a Rat Model.” Scandinavian Journal of Gastroenterology 41 (2): 155–60. doi:10.1080/00365520500206442.

11 Yu, Qinghua, Pengcheng Li, and Qian Yang. 2010. “Improving the Absorption of Earthworm Fibrinolytic Enzymes with Mucosal Enhancers.” Pharmaceutical Biology 48 (7): 816–21. doi:10.3109/13880200903283681.

12 Feinle-Bisset, Christine, and Fernando Azpiroz. 2013. “Dietary and Lifestyle Factors in Functional Dyspepsia.” Nature Reviews Gastroenterology & Hepatology 10 (3). Nature Publishing Group: 150–57. doi:10.1038/nrgastro.2012.246.

13 Aro, Pertti, Nicholas J. Talley, Jukka Ronkainen, Tom Storskrubb, Michael Vieth, Sven Erik Johansson, Elisabeth Bolling-Sternevald, and Lars Agréus. 2009. “Anxiety Is Associated With Uninvestigated and Functional Dyspepsia (Rome III Criteria) in a Swedish Population-Based Study.” Gastroenterology 137 (1). AGA Institute American Gastroenterological Association: 94–100. doi:10.1053/j.gastro.2009.03.039.

14 Wildner-Christensen, Mette, Jane Moller Hansen, and Ove B Schaffalitzky De Muckadell. 2006. “Risk Factors for Dyspepsia in a General Population: Non-Steroidal Anti-Inflammatory Drugs, Cigarette Smoking and Unemployment Are More Important than Helicobacter Pylori Infection.” Scandinavian Journal of Gastroenterology 41 (2): 149–54. doi:10.1080/00365520510024070

15 Thompson Coon, J, and E Ernst. 2002. “Systematic Review: Herbal Medicinal Products for Non-Ulcer Dyspepsia.” Alimentary Pharmacology & Therapeutics 16 (10): 1689–99. doi:10.1046/j.0269-2813.2002.01339.x.

16 May, B., S. Köhler, and B. Schneider. 2000. “Efficacy and Tolerability of a Fixed Combination of Peppermint Oil and Caraway Oil in Patients Suffering from Functional Dyspepsia.” Alimentary Pharmacology and Therapeutics14: 1671–77. doi:10.1046/j.1365-2036.2000.00873.x.

17 Talley, Nicholas J., and Nimish Vakil. 2005. “Guidelines for the Management of Dyspepsia.” American Journal of Gastroenterology 100 (10): 2324–37. doi:10.1111/j.1572-0241.2005.00225.x.

18 Brun, Rita, and Braden Kuo. 2010. “Functional Dyspepsia.” Therapeutic Advances in Gastroenterology 3 (3): 145–64. doi:10.1177/1756283X10362639.

19 Vanheel, Hanne, Maria Vicario, Tim Vanuytsel, Lukas Van Oudenhove, Cristina Martinez, Åsa V Keita, Nicolas Pardon, et al. 2014. “Impaired Duodenal Mucosal Integrity and Low-Grade Inflammation in Functional Dyspepsia.” Gut 63 (2): 262–71. doi:10.1136/gutjnl-2012-303857.

20 Rasool, Shahid, Shahab Abid, Mohammad Perwaiz Iqbal, Naseema Mehboobali, Ghulam Haider, and Wasim Jafri. 2012. “Relationship between Vitamin B12, Folate and Homocysteine Levels and H. Pylori Infection in Patients with Functional Dyspepsia: A Cross-Section Study.” BMC Research Notes 5 (1): 206. doi:10.1186/1756-0500-5-206.

21 Bischoff, Stephan C, Giovanni Barbara, Wim Buurman, Theo Ockhuizen, Jörg-Dieter Schulzke, Matteo Serino, Herbert Tilg, Alastair Watson, and Jerry M Wells. 2014. “Intestinal Permeability – a New Target for Disease Prevention and Therapy.” BMC Gastroenterology 14 (1): 189. doi:10.1186/s12876-014-0189-7.

22 Kindt, S., A. Tertychnyy, G. De Hertogh, K. Geboes, and J. Tack. 2009. “Intestinal Immune Activation in Presumed Post-Infectious Functional Dyspepsia.” Neurogastroenterology and Motility 21 (8): 832–38. doi:10.1111/j.1365-2982.2009.01299.x

 

23 Kassinen A, Krogius-Kurikka L, Makivuokko H, et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subject. Gastroenterology 2007; 133:24-33.

24 Annahazi A, Ferrier L, Bezirard V, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for andominal pain in constipation-predominant IBS. Am J Gastroenterol 2013; 108:1322-31.

25 Lee H, Park JH, Park DI, et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. Neurogastroenterol Motil 2013; 19:244-50.

26 Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36:1009-31.

27 Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 63 2014; doi:10.1136/gutjnl-2012-303857.

28 Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2012; 62:1160-8.

29 Dr. Ananya Mandal, supra fn. 79.

30 Kamath, P.S. et al., abnormal gallbladder motility in irritable bowel syndrome: evidence for target-organ defect. Am J Physiol 260:G815-G819, 1991.

31 Zong, L. et al., Preliminary experimental research on the mechanism of liver  bile secretion stimulated by peppermint oil. J Dig Dis. 2011 Aug: 12(4):295-301.

32 Balakrishnan, A., Therapeutic uses of peppermint—A review. J Pharm Sci & Res. Vol. 7(7), 2015, 474-476.

33https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/ucm054048.htm.